Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-08-08
2006-08-08
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023100, C536S023500, C536S024300, C536S024310, C536S024330, C530S300000
Reexamination Certificate
active
07087715
ABSTRACT:
The present invention relates to the discovery, identification and characterization of a novel tumor suppressor gene designated PARIS-1. The invention includes nucleotide sequences of the PARIS-1 gene and amino acid sequences of its encoded protein product(s), as well as fragments, derivatives and analogs thereof. The invention also includes the production of PARIS-1 proteins, fragments and derivatives and of antibodies specific for PARIS-1 gene products. The invention further comprises agents and compositions which can modulate the expression of PARIS-1 or PARIS-1 expression products to effect the proliferation of cells which express PARIS-1. One particular embodiment comprises agents and compounds which can slow or ablate the proliferation of prostate tumor cells.
REFERENCES:
patent: 6774216 (2004-08-01), Ruben et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0175739 (2003-09-01), Rosen et al.
patent: 2005/0250180 (2005-11-01), Jacobs et al.
Zhou et al. Biochem. Biophys. Res. Comm. 2002; 290: 830-8.
Saijo et al. Cancer Sci. Oct. 2004; 95 (10): 772-6.
Skolnick et al. Trends in Biotechnology. 2000; 18 (1): 34-9.
Bowie et al. Science. 1990; 257: 1306-10.
Kelland Eur. J. Cancer. Apr. 2004; 40 (6): 827-36.
Verma et al. Nature 1997, 389: 239-42.
Amalfitano et al. Current Gene Therapy 2002, 2: 111-33.
Patterson AP. Memorandum (Jan. 14, 2003); pp. 1-3.
Pandha et al. Current Opinion in Investigational Drugs 2000; 1 (1): 122-34.
Gura (Science. 1997; 278: 1041-1042.
Bergers et al. Current Opinion in Genetics and Development. 2000; 10: 120-7.
Arbieva et al., “High-Resolution Physical Map And Transcript Identification Of Prostate Cancer Deletion Interval On 8p22,”Genome Res.10:244-257 (2000).
Boel et al., “BAGE: A New Gene Encoding An Antigen Recognized On Human Melanomas By Cytolytic T Lymphocytes,”Immunity2:167-175 (1995).
Borysiewicz et al., “A Recombinant Vaccinia Virus Encoding Human Papillomavirus Types 16 and 18, E6 and E7 Proteins As Immunotherapy For Cervical Cancer,”Lancet347:1523-1527 (1996).
Brass et al., “Translation Initiation Factor eIF-4gamma Is Encoded By An Amplified Gene And Induces An Immune Response In Squamous Cell Lung Carcinoma,”Hum. Mol. Genet.6:33-39 (1997).
Brichard et al., “The Tyrosinase Gene Codes For An Antigen Recognized By Autologous Cytolytic T Lymphocytes On HLA-A2 Melanomas,”J. Exp. Med.178:489-495 (1993).
Brinkmann et al., “PAGE-1,An X Chromosome-LinkedGAGE-Like Gene That Is Expressed In Normal And Neoplastic Prostate, Testis, And Uterus,”Natl. Acad. Sci. USA95:10757-10762 (1998).
Carducci et al., “Prostate Cancer Treatment Strategies Based On Tumor-Specific Biological Principles: Future Directions,”Semin. Oncol.23:56-62 (1996).
Carey et al., “Cell Surface Antigens Of Human Malignant Melanoma: Mixed Hemadsorption Assays For Humoral Immunity To Cultured Autologous Melanoma Cells,”Proc. Natl. Acad. Sci. USA73:3278-3282 (1976).
Chen et al., “Isolation And Characterization OfPAGE-1 AndGAGE-7,” J. Biol. Chem.273:17618-17625 (1998).
Cormier et al., “Enhancement Of Cellular Immunity In Melanoma Patients Immunized With A Peptide From MART-1/Melan A,”Cancer J. Sci. Am.3:37-44 (1997).
Coulie et al., “A New Gene Coding For A Differentiation Antigen Recognized By Autologous Cytolytic T Lymphocytes On HLA-A2 Melanomas,”J. Exp. Med.180:35-42 (1994).
De Plaen et al., “Structure, Chromosomal Localization, And Expression Of 12 Genes Of TheMAGEFamily,”Immunogenetics40:360-369 (1994).
Falk et al., “Allele-Specific Motifs Revealed By Sequencing Of Self-Peptides Eluted From MHC Molecules,”Nature351:290-296 (1991).
Gaugler et al., “Human Gene MAGE-3 Codes For An Antigen Recognized On A Melanoma By Autologous Cytolytic T Lymphocytes,”J. Exp. Med.179:921-930 (1994).
Güre et al., “Human Lung Cancer Antigens Recognized By Autologous Antibodies: Defenition Of A Novel cDNA Derived From The Tumor Suppressor Gene Locus On Chromosome 3p21.3,”Cancer Res.58:1034-1041 (1998).
Horoszewicz et al., “LNCaP Model of Human Prostatic Carcinoma”Cancer Res.43:1809-1818 (1983).
Hrouda et al., “Gene Therapy For Prostate Cancer,”Gene Ther.3:845-852 (1996).
Hsu et al., “Vaccination Of Patients With B-Cell Lymphoma Using Autologous Antigen-Pulsed Dendritic Cells,”Nat. Med.2:52-58 (1996).
Isaacs et al., “Molecular Biology Of Prostate Cancer,”Semin. Oncol.21:514-521 (1994).
Isaacs, “Molecular Genetics Of Prostate Cancer,”Cancer Surv.25:357-379 (1995).
Jäger et al., “Simultaneous Humoral and Cellular Immune Response Against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-Binding Peptide Epitopes,”J. Exp. Med.187:265-270 (1998).
Kawakami et al., “Cloning Of The Gene Coding For A Shared Human Melanoma Antigen Recognized By Autologous T Cells Infiltrating Into Tumor,”Proc. Natl. Acad. Sci. USA91:3515-3519 (1994).
Kawakami et al., “Identification Of A Human Melanoma Antigen Recognized By Tumor-Infiltrating Lymphocytes Associated WithIn VivoTumor Rejection,”Proc. Natl. Acad. Sci. USA91:6458-6462 (1994).
Kim et al., “Dendritic Cells Infected With Poxviruses Encoding MART-1/Melan A Sensitive T Lymphocytes In Vitro,”J. Immunother.20:276-286 (1997).
Kozak, “At Least Six Nucleotides Preceding The AUG Initiator Codon Enhance Translation In Mammalian Cells,”J. Mol. Biol.196:947-950 (1987).
Kozak, “Possible Role Of Flanking Nucleotides In Recognition Of The AUG Initiator Codon By Eukaryotic Ribosomes,”Nuc. Acids. Res.9:5233-5252 (1981).
Landis et al., “Cancer Statistics,1999”CA Cancer J. Clin.49:8-31 (1999).
Mandelboim et al., “CTL Induction By A Tumour-Associated Antigen Octapeptide Derived From A Murine Lung Carcinoma,”Nature369:67-71 (1994).
Mandelboim et al., “CTL Induction By A Tumour-Associated Antigen Octapeptide Derived From A Murine Lung Carcinoma,”Nature390:643 (1997).
McAneny et al., “Results Of A Phase 1 Trial Of A Recombinant Vaccinia Virus That Expresses Carcinoembryonic Antigen In Patients With Advanced Colorectal Cancer,”Ann. Surg. Oncol.3:495-500 (1996).
Nestle et al., “Vaccination Of Melanoma Patients With Peptide- Or Tumor Lystate-Pulsed Dendritic Cells,”Nat. Med.4:328-332 (1998).
Nupponen et al., “Genetic Alterations In Prostate Cancer Cell Lines Detected By Comparative Genomic Hybridization,”Cancer Genet. Cytogenet.101:53-57 (1998).
Pass et al., “Immunization Of Patients With Melanoma Peptide Vaccines: Immunologic Assessment Using The ELISPOT Assay,”Cancer J. Sci. Am.4:316-323 (1998).
Pfreundschuh et al., “Serological Analysis Of Cell Surface Antigens Of Malignant Human Brain Tumors,”Proc. Natl. Acad. Sci. USA75:5122-5126 (1978).
Ponder, “Inherited Predispositions To Cancer,”TIG6:213-218 (1990).
Reynolds et al., “HLA-Independent Heterogeneity of CD8+T Cell Responses To MAGE-3, Melan-A/Mart-1, gp100, Tyrosinase, MC1R, and TRP-2 In Vaccine-Treated Melanoma Patients,”J. Immunol.161:6970-6976 (1998).
Rosenberg et al., “Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens,”J. Natl. Cancer Inst.90:1894-1900 (1998).
Rosenberg et al., “Immunologic And Therapeutic Evaluation Of A Synthetic Peptide Vaccine For The Treatment Of Patients With Metastatic Melanoma,”Nat. Med.4:321-327 (1998).
Royai et al., “Preclinical Model Of Prostate Cancer,”Semin. Oncol.23:35-40 (1996).
Sahin et al., “Human Neoplasms Elicit Multiple Specific Immune Responses In The Autologous Host,”Proc. Natl. Acad. Sci. USA92:11810-11813 (1995).
Salgaller et al., “Immunization Against Epitopes In The Human Melanoma Antigen gp100 Followin
Northwest Biotherapeutics, Inc.
Rawlings Stephen L.
Townsend and Townsend / and Crew LLP
LandOfFree
Human paris-1 antigen and nucleic acids: diagnostic and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human paris-1 antigen and nucleic acids: diagnostic and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human paris-1 antigen and nucleic acids: diagnostic and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714990